Xu, Yingying
Wang, Yakun
Gong, Jifang
Zhang, Xiaotian
Peng, Zhi
Sheng, Xinan
Mao, Chenyu
Fan, Qingxia
Bai, Yuxian
Ba, Yi
Jiang, Da
Yang, Fen
Qi, Changsong
Li, Jian
Wang, Xicheng
Zhou, Jun
Lu, Ming
Cao, Yanshuo
Yuan, Jiajia
Liu, Dan
Wang, Zhenghang
Fang, Jianmin
Shen, Lin http://orcid.org/0000-0002-8798-4756
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
https://doi.org/10.1007/s10120-021-01168-7
Article History
Received: 11 October 2020
Accepted: 1 February 2021
First Online: 4 May 2021
Compliance with ethical standards
:
: None of the authors declare any conflict of interest.
: This clinical trial was approved by the ethics committee of Peking University Cancer Hospital. The reference number was 2015L02291. The ethical review opinion is showed in supplementary Fig. 3 and supplementary Fig. 4. This clinical trial complied with the Declaration of Helsinki, the good clinical practice (GCP) promulgated by the SFDA, and relevant regulations.
: All subjects completed written informed consent prior to study entry.